ClinicalTrials.gg
RecruitingNCT04621435Updated Jun 4, 2026

Imaging of Solid Tumors Using FAP-2286

A Phase 1 interventional study of Gallium-68 labelled (68Ga-) FAP-2286 and Positron Emission Tomography (PET) imaging in Solid Tumors, Adult and Metastatic Cancer, sponsored by Thomas Hope. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Thomas Hope · Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Dec 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
191
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
320th of 1,866
191 · median 43
Started
2020
with 88 others
Phase 1
710 of 2,057
127 open now
Primary completion
2026-12
later than 127 of 542 live
Registered
1,468th of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 320th largest by planned enrollment of the 1,866 interventional ones that give a count, is one of 89 that started in 2020, is one of 710 in phase 1, reaches primary completion later than 127 of the 542 other live ones, and was the 1,468th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.

Read the detailed description

Initially the investigator(s) will focus on imaging breast, pancreas, sarcoma, prostate cancer, bladder cancer, colon cancer, and head and neck cancer.

STUDY AIMS

  1. Determine the dosimetry for gallium-68 labelled (68Ga-) and 64Cu- FAP-2286.
  2. Evaluate the uptake and retention of radiotracer in a variety of solid tumors with FAP-2286.
  3. Evaluate the ability of FAP-2286 to detect metastatic disease.

PRIMARY OBJECTIVES

  1. All cohorts: Safety of 68Ga- and 64Cu-FAP-2286.
  2. Cohort 1a: determine the organ dosimetry of 68Ga-FAP-2286.
  3. Cohort 1b: determine the organ dosimetry of 64Cu-FAP-2286.
  4. Cohort 2: To assess the feasibility of detecting tumor uptake using FAP-2286.
  5. Cohort 3: To determine the feasibility of detecting metastatic disease using FAP-2286.

EXPLORATORY OBJECTIVES

  1. To detect the sensitivity of FAP-2286 PET compared to conventional imaging for the detection of metastatic disease, and when available sensitivity compared to Fluorodeoxyglucose (FDG) PET (FDG-PET).
  2. Correlation of FAP-2286 uptake with FAP expression determined by immunohistochemistry.
  3. Compare biodistribution of 68Ga-FAP-2286 and 64Cu-FAP-2286 in normal organs and blood pool based on renal function.
  4. Determine impact of administered dose of FAP-2286 on image quality.
  5. Compare the feasibility of detecting tumor uptake using 68Ga-FAP-2286 and 64Cu-FAP-2286

A repeat radiolabeled FAP-2286 PET may be obtained after initiation of subsequent treatment in order to evaluate changes in PET uptake due to treatment effect. Participants will be followed through the day of the last injection of radiolabeled FAP-2286 for evaluation of adverse events.

03

Conditions studied

  • Solid Tumors, Adult
  • Metastatic Cancer

Browse trials for

Keywords

  • PET
  • 68Ga-FAP-2286
  • 64Cu-FAP-2286
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >= 18 years.
  2. Histopathologically confirmed solid tumors in one of the following cohorts:

    a. Cohort 1 (n=11): is not required for this cohort.

    i. Agnostic to tumor type.

    b. Cohort 2 (n=95): disease present on conventional imaging defined as having 1.1 measurable disease or multiple bone metastases. Note: Presence of absence of metastatic disease for eligibility determination will be assessed by reviewing medical records. Screening imaging will not be conducted for this study.

    i. confirmed breast cancer, pancreatic adenocarcinoma, sarcoma, castrate-resistant prostate cancer, bladder cancer, colon cancer, or other cancer type.

    c. Cohort 3 (n=85): No evidence of metastatic disease as defined as the absence of RECIST 1.1 measurable disease or bone metastases. Note: Presence of absence of metastatic disease for eligibility determination will be assessed by reviewing medical records. Screening imaging will not be conducted for this study.

    i. Participants can be imaged at initial staging with what is judged by the treating physician to be high risk disease and where the presence of metastatic disease would greatly impact treatment planning and prognosis. Participants may also be imaged after therapy (surgery, chemotherapy or radiation therapy) if in the determination of the treating physician or investigator there is a high risk of disease recurrence that would also impact treatment plan and/or prognosis.

    ii. Pathologically confirmed head and neck cancer, bladder cancer, or other cancer type.

  3. Ability to understand a written document, and the willingness to sign it.

Exclusion criteria

Exclusion Criteria:

  1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
  2. Known pregnancy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
191 participants (estimated)

Study arms

  • Experimental
    CLOSED - 68Ga-Dosimetry population (Cohort 1a)

    PET imaging will begin 30 +/-10 minutes, 60 +/-15 minutes and 120 +/-20 minutes after injection of 68Ga-FAP-2286. Contrast may be administered if clinically indicated.

    Drug: Gallium-68 labelled (68Ga-) FAP-2286 · Procedure: Positron Emission Tomography (PET) imaging

  • Experimental
    CLOSED - 64Cu-Dosimetry population (Cohort 1b)

    PET imaging will begin 60±15 minutes, 240±30 minutes after injection, and a second PET imaging will be performed 24±2 hours after initial injection of 64Cu-FAP-2286. Contrast may be administered if clinically indicated.

    Procedure: Positron Emission Tomography (PET) imaging · Drug: Copper-64 labeled (64Cu-) FAP-2286

  • Experimental
    Participants with metastatic disease (Cohort 2)

    Participants with metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga- or 64Cu- FAP-2286. Contrast may be administered if clinically indicated.

    Drug: Gallium-68 labelled (68Ga-) FAP-2286 · Procedure: Positron Emission Tomography (PET) imaging · Drug: Copper-64 labeled (64Cu-) FAP-2286

  • Experimental
    Participants without metastatic disease (Cohort 3)

    Participants without metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga- or 64Cu- FAP-2286. Contrast may be administered if if clinically indicated.

    Drug: Gallium-68 labelled (68Ga-) FAP-2286 · Procedure: Positron Emission Tomography (PET) imaging · Drug: Copper-64 labeled (64Cu-) FAP-2286

Interventions

  • DrugGallium (68GA) rofapitide tetraxetanStudies of Gallium (68GA) rofapitide tetraxetanGallium (68GA) rofapitide tetraxetan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging

    Also known as: 68Ga-FAP-2286

  • ProcedurePositron Emission Tomography (PET) imaging

    Participants will be scanned for approximately 30 to 45 minutes

    Also known as: PET

  • DrugCopper-64 labeled (64Cu-) FAP-2286

    The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging

    Also known as: 64Cu-FAP-2286

06

What researchers measure

Primary outcomes

  1. Count of participants with treatment-emergent adverse events

    The frequency and severity of treatment emergent adverse events following FAP-2286 injection will be descriptively reported as classified and graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0

    Time frame: Until end of day on the day of the injection (1 day total)

  2. Proportion of radiation-absorbed doses of radiolabeled FAP-2286 (Cohorts 1a/1b only)

    Volumes of interest of 68Ga- and 64Cu- will be drawn around regions identified on the scans, including the liver, spleen, kidneys, urinary bladder, the central sacrum (for hematopoietic marrow) and whole body. Data will be fitted using the Simulation, Analysis, and Modeling Software II (SAAM II) software. Time integrals of activity will be entered into the Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA/EXM) software, using the reference adult model. The results from all patients enrolled will be combined to allow the calculation of mean, standard deviation (SD), and range of radiation-absorbed doses to individual organs

    Time frame: Up to 3 days

  3. Standardized Uptake Values (SUVs) (Cohort 2 only)

    The maximum Standardized Uptake Value (SUVmax) will be calculated for up to five lesions in each patient, with mediastinal blood pool being used as background activity.

    Time frame: Up to 3 days

  4. Tumor-to-background (TBR) Ratio (Cohort 2 only)

    TBR ratios will be calculated for up to five lesions in each patient, with mediastinal blood pool being used as background activity. The median and range of the measured TBRs will be reported across all RECIST measurable lesions as a table broken down by location (organ metastases, nodal metastases and bone metastases).

    Time frame: Up to 3 days

  5. Proportion of positive lesions on FAP-2286 PET (Cohort 3 only)

    Conventional imaging or CT portion of PET/CT scan will be reviewed in conjunction with the FAP-2286 PET images. Lesions will be characterized as positive on FAP-2286 PET if uptake is greater than 1.5 times higher than mediastinal blood pool and uptake cannot be attributed to physiologic or inflammatory reasons. Conventional imaging or CT portion of PET/CT scan will be interpreted as positive by each lesion if the short axis dimension of lymph nodes is greater than 1 centimeter (cm), and organ metastases measure greater than 1 cm in long axis. The gold standard will be the combination of conventional imaging and FAP-2286 PET in combination with clinical follow-up and histopathology (if available). The number of lesions detected by each modality will be compared and sensitivity will be computed. Since this is a proof-of-concept study, it is not powered for the test of agreement. Nevertheless, the agreement will be tested using McNemar's test.

    Time frame: Up to 3 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kline B, Yadav S, Seo Y, Ippisch RC, Castillo J, Aggarwal RR, Kelley RK, Behr SC, Flavell RR, Lawhn-Heath C, Melisko M, Rugo HS, Wang V, Yom SS, Ha P, Jiang F, Hope TA. 68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG. J Nucl Med. 2024 Jun 3;65(6):938-943. doi: 10.2967/jnumed.123.267281. PubMed 38697672 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Dec 2026, 72 months after the start.

Of 209 non-industry phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 72 months is above that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2020
First posted
Nov 9, 2020
StartActual
Dec 14, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04621435
Lead sponsor
Thomas Hope
Collaborators
Society of Abdominal Radiology
Responsible party
Thomas Hope (Principal Investigator, University of California, San Francisco) — Sponsor-investigator
First posted
Nov 9, 2020
Start date
Dec 14, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 4, 2026

Study contacts

Maya Aslam
Contact
Maya.Aslam@ucsf.edu
877-827-3222
Thomas Hope, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium (68GA) rofapitide tetraxetan

Start the discussion